The Latest Cardiac and Vascular News
Sirtex brings an innovative liver cancer treatment delivery system to Europe, enhancing options for physicians and their patients. WOBURN, Mass. (September 16, 2024) – Sirtex Medical (“Sirtex”), a leading manufacturer of interventional treatment solutions, today announced that it has received certification according to Medical Device Regulation (EU) 2017/745 for SIR-Spheres® […]
LAVA clinical trial underway for potential first FDA-approved liquid embolic system for a peripheral vascular indication WOBURN, Mass., April 19, 2021 /PRNewswire/ — Sirtex Medical (Sirtex), a leading manufacturer of targeted liver cancer therapies, and BlackSwan Vascular, Inc. (BlackSwan), a Bay Area-based private company developing groundbreaking therapies in endovascular embolization, announced that the first […]
Industry veteran to lead Medical and Clinical Affairs to advance clinical trials and accelerate further development of cancer therapies WOBURN, Mass., June 3, 2020 /PRNewswire/ — Sirtex Medical US Holdings, Inc. (“Sirtex”), a leading manufacturer of targeted liver cancer therapies, announced the appointment of Dr. Mark A. Turco, FACC, as Global Chief Medical Officer and […]
PALO ALTO, Calif., Jan. 30, 2018 /PRNewswire/ — Varian (NYSE: VAR) today announced that it will webcast a conference call to discuss the details of the agreement, also announced today, to acquire all the outstanding shares of Sirtex Medical. Sirtex is an Australia-based global life sciences company focused on interventional oncology therapies, that is […]
PUBLIC RELEASE: 22-APR-2017 April 22, 2017, Amsterdam, The Netherlands: Results of the SARAH trial presented today demonstrate that SIRT resulted in median overall survival (OS) of 8.0 months compared to 9.9 months with sorafenib (p=0.179), in patients with locally advanced and inoperable hepatocellular carcinoma (HCC). The trial, presented at The International […]
